BioSpace News Archive

POINT Biopharma Inc. announced that it has successfully dosed multiple patients in its Phase 3 SPLASH study evaluating the efficacy of PNT2002, the Company’s investigational 177Lu-PSMA targeted radioligand therapy for patients with PSMA expressing metastatic castration resistant prostate cancer who are not eligible for chemotherapy.

Global patent jurisdictions continue to recognize Microbot Medical Inc.’s innovative ‘One & Done’ guidewire technology, as the Israel Intellectual Property Office has issued a Notice of Allowance.

Paul J. Diaz, president and CEO of Myriad Genetics, a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Goldman Sachs 2021 Virtual Global Healthcare Conference at 8:50 a.m. EST on June 10, 2021.

Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptorpositive breast cancer

The Nomination Committee of Elekta proposes that the 2021 Annual General Meeting re-elect Board members Laurent Leksell, who is also proposed to be re-elected as Chairman of the Board, Caroline Leksell Cooke, Johan Malmquist, Wolfgang Reim, Jan Secher, Birgitta Stymne Göransson and Cecilia Wikström.

According to the report, the global NICU catheters market was valued at US$ 400 Mn in 2020 and is projected to expand at a CAGR of 4.5% from 2021 to 2031.

The population of people affected by a number of neurological conditions has expanded at a rapid pace in the past few years across the globe, making these diseases a leading cause of disability.

The pandemic has disrupted healthcare systems worldwide, with hospitals being overwhelmed due to the increasing influx of patients.

Biodesix, Inc., a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their data.

Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial